• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在 Centiloids 中探究可靠的淀粉样蛋白沉积：来自 AMYPAD 预后和自然史研究的结果。

Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.

机构信息

Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.

Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.

出版信息

Alzheimers Dement. 2024 May;20(5):3429-3441. doi: 10.1002/alz.13761. Epub 2024 Apr 4.

DOI:10.1002/alz.13761
PMID:38574374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11095430/
Abstract

INTRODUCTION

To support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations.

METHODS

A total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease-Prognostic and Natural History Study (AMYPAD-PNHS) and Insight46 who underwent [F]flutemetamol, [F]florbetaben or [F]florbetapir amyloid-PET were included. A normative strategy was used to define reliable accumulation by estimating the 95 percentile of longitudinal measurements in sub-populations (N = 101/750, N = 35/382) expected to remain stable over time. The baseline CL threshold that optimally predicts future accumulation was investigated using precision-recall analyses. Accumulation rates were examined using linear mixed-effect models.

RESULTS

Reliable accumulation in the PNHS was estimated to occur at >3.0 CL/year. Baseline CL of 16 [12,19] best predicted future Aβ-accumulators. Rates of amyloid accumulation were tracer-independent, lower for APOE ε4 non-carriers, and for subjects with higher levels of education.

DISCUSSION

Our results support a 12-20 CL window for inclusion into early secondary prevention studies. Reliable accumulation definition warrants further investigations.

摘要

简介

为了支持专注于早期干预的临床试验设计，我们的研究基于 Centiloids（CL）在痴呆前人群中确定了可靠的早期淀粉样蛋白-β（Aβ）积累。

方法

共有 1032 名来自淀粉样蛋白成像预防阿尔茨海默病-预后和自然史研究（AMYPAD-PNHS）和 Insight46 的参与者接受了 [F]flutemetamol、[F]florbetaben 或 [F]florbetapir 淀粉样蛋白-PET。使用规范策略通过估计预期随时间保持稳定的亚人群（N = 101/750，N = 35/382）的纵向测量的 95 百分位数来定义可靠的积累。使用精度-召回分析研究了最佳预测未来积累的基线 CL 阈值。使用线性混合效应模型检查了积累率。

结果

PNHS 中的可靠积累估计为 >3.0 CL/年。16 [12,19]的基线 CL 最佳预测了未来的 Aβ 积累者。淀粉样蛋白积累的速度与示踪剂无关，APOE ε4 非携带者和受教育程度较高的受试者的积累速度较低。

讨论

我们的结果支持将 12-20 CL 窗口纳入早期二级预防研究。可靠积累的定义需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/4d5d2e420277/ALZ-20-3429-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/9c6eae88bfba/ALZ-20-3429-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/312338f7408b/ALZ-20-3429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/dea0c6af913f/ALZ-20-3429-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/66575aadaee5/ALZ-20-3429-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/7031565903af/ALZ-20-3429-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/4d5d2e420277/ALZ-20-3429-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/9c6eae88bfba/ALZ-20-3429-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/312338f7408b/ALZ-20-3429-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/dea0c6af913f/ALZ-20-3429-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/66575aadaee5/ALZ-20-3429-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/7031565903af/ALZ-20-3429-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d76/11095430/4d5d2e420277/ALZ-20-3429-g006.jpg

相似文献

1
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.在 Centiloids 中探究可靠的淀粉样蛋白沉积：来自 AMYPAD 预后和自然史研究的结果。
Alzheimers Dement. 2024 May;20(5):3429-3441. doi: 10.1002/alz.13761. Epub 2024 Apr 4.
2
Longitudinal head-to-head comparison of C-PiB and F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.在一项针对显性遗传性阿尔茨海默病的抗淀粉样蛋白β单克隆抗体的 2/3 期临床试验中，进行 C-PiB 和 F-氟比他滨 PET 的纵向对头比较。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5.
3
Amyloid-PET imaging predicts functional decline in clinically normal individuals.淀粉样蛋白 PET 成像可预测临床正常个体的功能下降。
Alzheimers Res Ther. 2024 Jun 17;16(1):130. doi: 10.1186/s13195-024-01494-9.
4
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.以多中心 PET 研究方法验证 centiloids 中淀粉样 PET 阳性阈值。
Alzheimers Res Ther. 2021 May 10;13(1):99. doi: 10.1186/s13195-021-00836-1.
5
Expression of regional brain amyloid-β deposition with Flutemetamol in Centiloid scale -a multi-site study.Flutemetamol 在 Centiloid 标度上对区域性脑淀粉样蛋白-β 沉积的表达-一项多中心研究。
Neuroradiology. 2024 Sep;66(9):1537-1551. doi: 10.1007/s00234-024-03364-5. Epub 2024 Apr 27.
6
Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology.使用标准 Centiloid、基于 MRI 和无 MRI 的 CapAIBL 方法对 F-氟脱氧葡萄糖定量结果进行比较：与组织病理学的验证。
Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.
7
Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [F] flutemetamol amyloid PET study.定义预测记忆门诊患者长期进展为痴呆的百分位阈值：一项 [F] 氟替美莫淀粉样 PET 研究。
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):302-310. doi: 10.1007/s00259-020-04942-4. Epub 2020 Jun 29.
8
Implementing the centiloid transformation for C-PiB and β-amyloid F-PET tracers using CapAIBL.使用 CapAIBL 实现 C-PiB 和 β-淀粉样蛋白 F-PET 示踪剂的百分位数转换。
Neuroimage. 2018 Dec;183:387-393. doi: 10.1016/j.neuroimage.2018.08.044. Epub 2018 Aug 18.
9
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses.正电子发射断层扫描（PET）重建对横断面和纵向分析中淀粉样蛋白-β定量的影响。
J Nucl Med. 2024 May 1;65(5):781-787. doi: 10.2967/jnumed.123.266188.
10
Early detection of amyloid load using F-florbetaben PET.使用 F-氟脱氧葡萄糖 PET 进行淀粉样蛋白负荷的早期检测。
Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6.

引用本文的文献

1
Reliability of Automated Amyloid PET Quantification: Real-World Validation of Commercial Tools Against Centiloid Project Method.淀粉样蛋白PET自动定量的可靠性：商业工具相对于百分中心项目法的真实世界验证
Tomography. 2025 Jul 30;11(8):86. doi: 10.3390/tomography11080086.
2
Revisiting Centiloids using AI.利用人工智能重新审视厘泊单位
Res Sq. 2025 Jul 8:rs.3.rs-7015694. doi: 10.21203/rs.3.rs-7015694/v1.
3
Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load.两种淀粉样蛋白PET缩放方法的比较及临界值：百分等级量表和淀粉样蛋白-β负荷

本文引用的文献

1
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan.使用霍夫曼体模扫描对多中心PET研究中的脑PET图像进行标准化处理。
EJNMMI Phys. 2023 Oct 31;10(1):68. doi: 10.1186/s40658-023-00588-x.
2
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
3
Trial of Solanezumab in Preclinical Alzheimer's Disease.在临床前阿尔茨海默病中进行的 Solanezumab 试验。
Ann Nucl Med. 2025 Apr 26. doi: 10.1007/s12149-025-02051-6.
4
Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.主观认知下降个体的基线淀粉样蛋白PET定量可识别淀粉样蛋白积累和认知恶化风险：FACEHBI研究
Eur J Nucl Med Mol Imaging. 2025 Apr 23. doi: 10.1007/s00259-025-07270-7.
5
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.淀粉样蛋白PET百分标准值在临床试验和研究中的实际应用概述。
Neuroimage Clin. 2025 Mar 10;46:103765. doi: 10.1016/j.nicl.2025.103765.
6
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.阿尔茨海默病淀粉样蛋白PET和脑脊液生物标志物临床应用的考量
Alzheimers Dement. 2025 Mar;21(3):e14528. doi: 10.1002/alz.14528.
7
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.氟贝他班淀粉样蛋白PET临床研究与常规使用经验：上市后十年的见解
Pharmaceuticals (Basel). 2024 Dec 7;17(12):1648. doi: 10.3390/ph17121648.
8
Enhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models.增强淀粉样蛋白PET定量：使用潜在扩散模型的MRI引导超分辨率
Life (Basel). 2024 Dec 1;14(12):1580. doi: 10.3390/life14121580.
9
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.AMYPAD联盟关于临床使用背景的Centiloid建议。
Alzheimers Dement. 2024 Dec;20(12):9037-9048. doi: 10.1002/alz.14336. Epub 2024 Nov 20.
10
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.胶质纤维酸性蛋白、阿尔茨海默病病理学与认知衰退的关联
Brain. 2024 Dec 3;147(12):4094-4104. doi: 10.1093/brain/awae211.
N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17.
4
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact.预防阿尔茨海默病淀粉样蛋白成像联盟：一项具有全球影响力的欧洲合作项目。
Front Neurol. 2023 Jan 20;13:1063598. doi: 10.3389/fneur.2022.1063598. eCollection 2022.
5
Longitudinal changes in F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations.载脂蛋白 E4 携带者与非携带者认知正常人群中 F-Flutemetamol 淀粉样蛋白负荷的纵向变化：方法学考虑。
Neuroimage Clin. 2023;37:103321. doi: 10.1016/j.nicl.2023.103321. Epub 2023 Jan 5.
6
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
7
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.RSNA QIBA 淀粉样蛋白 PET 成像生物标志物分析用于脑淀粉样蛋白定量。
J Nucl Med. 2023 Feb;64(2):294-303. doi: 10.2967/jnumed.122.264031. Epub 2022 Sep 22.
8
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.度胺能减少淀粉样蛋白后与 tau 病理和临床结局的关联：TRAILBLAZER-ALZ 随机临床试验。
JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793.
9
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究：阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
10
β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.β-淀粉样蛋白 PET 纵向研究的协调：在 AIBL、ADNI 和 OASIS3 中的应用。
Neuroimage. 2022 Nov 15;262:119527. doi: 10.1016/j.neuroimage.2022.119527. Epub 2022 Jul 30.